Tyrosine kinase inhibitors – should we worry about cardiovascular complications?
Journal Title: OncoReview - Year 2017, Vol 7, Issue 2
Abstract
Small-molecular tyrosine kinase inhibitors constitute an effective therapeutic option in patients with hematologic malignancies and solid tumours. On the other hand, the significance of cardiovascular adverse events associated with their use is often emphasised. The events include arterial hypertension, heart failure, coronary disease/acute coronary syndromes, and long QT syndrome. The paper discusses the underlying mechanisms behind cardiovascular events associated with the treatment that involves tyrosine kinase inhibitors, and presents preventive and therapeutic options available in clinical practice. Awareness of the potential cardiovascular complications, regular follow-up, early diagnosis and initiation of appropriate treatment, combined with close collaboration with cardiology specialists, may enhance the benefits of long-term TKI therapy.
Authors and Affiliations
Katarzyna Styczkiewicz, Dariusz Sawka, Marek Styczkiewicz
Keywords
Related Articles
- EP ID EP189722
- DOI 10.24292/01.OR.300617.3
- Views 222
- Downloads 0
Arterial hypertension related to sunitinib
Hypertension is a common concomitant disease in patients with renal carcinoma and a frequent complication of sunitinib therapy. Blocking of VEGF-dependent pathway leads to endothelial dysfunction, reduced nitric oxide pr...
Papillary renal cell carcinoma – case report of a patient with disseminated disease treated with pazopanib with several years of survival against reviewing current literature
Papillary renal cell carcinoma is the second most common histological type of renal cell carcinoma with distinct cytogenetics, histology and prognosis. It exhibits significantly poorer response to molecular targeted ther...
Nieodwracalne inhibitory kinaz tyrozynowych receptorów rodziny naskórkowego czynnika wzrostu – nowa, obiecująca strategia terapeutyczna
Inhibitory kinaz tyrozynowych receptorów rodziny naskórkowego czynnika wzrostu (ErbB) znalazły miejsce w rutynowej praktyce klinicznej. Niestety, u części chorych nie stwierdza się odpowiedzi na leczenie pomimo istnienia...
Dylematy w leczeniu raka nerki - pazopanib
Postęp w leczeniu systemowym przerzutowego raka nerki związany jest z rejestracją nowych leków. Przyniosło to poprawę wyników leczenia, ale zmusza również do dokonywania wyboru leku. Decyzja ta jest szczególnie istotna w...
Depression in patients with cancer. Diagnosis and treatment in clinical practice
Comorbidity between depression and cancer is a common condition. It depends on many variables such as cancer location or phase of the illness, but as a rule this situation should not be neglected. The reasons for providi...